Table 1.
Demographic and clinical characteristics of 511 newly diagnosed AML patients in the study set
| All cases | Treated
|
P | ||||
|---|---|---|---|---|---|---|
| All | Lowest 3rd | Middle 3rd | Highest 3rd | |||
| N | 511 | 414 | 129 | 142 | 144 | |
| Gender | ||||||
| Male/female | 291:220 | 218:197 | 73:56 | 71:70 | 75:69 | 0.66 |
| Age | ||||||
| Min | 15.8 | 17.4 | 27 | 18.8 | 17.39 | 0.32 |
| Max | 87.23 | 86.8 | 86.6 | 85.6 | 86.8 | |
| Median | 65.7 | 64.16 | 64.24 | 65.3 | 63.58 | |
| FAB | ||||||
| M0 | 5.7% | 5.1% | 3.9% | 6.3% | 4.9% | 0.67 |
| M1 | 10.8% | 11.6% | 8.5% | 11.3% | 14.6% | 0.29 |
| M2 | 33.1% | 37.0% | 44.2% | 44.4% | 22.9% | 0.00002 |
| M4 | 22.7% | 23.4% | 19.4% | 22.5% | 27.8% | 0.26 |
| M5 | 10.0% | 9.9% | 5.4% | 4.2% | 19.4% | 0.000008 |
| M6 | 5.3% | 5.1% | 6.2% | 4.9% | 4.2% | 0.72 |
| M7 | 2.0% | 1.9% | 2.3% | 0.7% | 2.8% | 0.41 |
| Unknown | 3.3% | 0.7% | 0.8% | 1.4% | 0.0% | |
| RAEBT | 7.2% | 5.6% | 9.3% | 4.2% | 3.5% | 0.068 |
| WHO* | ||||||
| Abnormal cytogenetics | 9.2% | 10.4% | 13.2% | 11.3% | 8.3% | 0.57 |
| Multilineage dysplasia | 21.5% | 18.8% | 24.8% | 18.3% | 13.9% | 0.16 |
| Therapy related | 14.3% | 12.8% | 16.3% | 12.0% | 10.4% | 0.36 |
| Not in Others | 55.0% | 58.0% | 45.0% | 58.5% | 68.8% | 0.0008 |
| Cyto† | ||||||
| Favorable | 6.7% | 8.0% | 10.9% | 10.6% | 2.8% | 0.019 |
| Intermediate | 44.0% | 45.2% | 37.2% | 45.1% | 52.1% | |
| Unfavorable | 49.3% | 47.1% | 51.9% | 44.4% | 45.1% | |
| FLT3 | ||||||
| ITD | 14.9% | 17.9% | 7.0% | 15.5% | 29.9% | 0.000004 |
| D835 | 3.1% | 3.9% | 1.6% | 4.2% | 5.6% | 0.045 |
| Both | 1.6% | 1.9% | 0.0% | 2.8% | 2.8% | 0.16 |
| Zubrod PS | ||||||
| 3 or 4 | 3.3% | 3.1% | 1.6% | 2.8% | 4.9% | 0.42 |
| AHD | ||||||
| ≥2 Mo | 39.9% | 37.4% | 48.8% | 34.5% | 29.9% | 0.004 |
| Infection | ||||||
| Yes | 19.8% | 22.2% | 14.0% | 21.1% | 30.6% | 0.004 |
| WBC | ||||||
| Median | 8.8 | 9.9 | 3.55 | 9.2 | 30.1 | <0.00001 |
| Platelet | ||||||
| Median | 56 | 55.5 | 53 | 53.5 | 59 | 0.11 |
| Hemoglobin | ||||||
| Median | 9.6 | 9.6 | 9.7 | 9.5 | 9.5 | 0.56 |
| % marrow blast | ||||||
| Median | 46 | 50 | 38 | 46 | 70 | <0.00001 |
| % blood blast | ||||||
| Median | 18 | 20.5 | 8 | 20.5 | 48 | <0.00001 |
| Response | ||||||
| CR | NA‡ | 55.8% | 59.7% | 59.2% | 48.6% | 0.11 |
| Resistant | NA | 34.3% | 31.8% | 31.7% | 38.9% | 0.34 |
| Fail | NA | 10.1% | 8.5% | 9.2% | 12.5% | 0.49 |
| Relapse | NA | 61.5% | 62.3% | 57.1% | 64.3% | 0.64 |
| Alive | NA | 25.1% | 24.8% | 33.8% | 16.7% | |
| Overall survival, median, wk | NA | 48.7 | 64.85 | 60.14 | 33.714 | 0.0002 |
| Remission duration, median, wk | NA | 45.57 | 41 | 52.9 | 34.7 | 0.12 |
NOTE: The demographics of only those that were treated is shown in the second column and the distribution based on the ratio of phospho to total FOXO3A levels are shown in the next three columns. The P values refer to comparisons of the 3 PT-FOXO3A groups.
Abbreviation: NA, not applicable.
*
Based on the 2008 classification schema.
†
Favorable, t(8:21) or inversion(16); intermediate, Diploid or -y; unfavorable, all others including −5, −7, +8, and t(6:9); miscellaneous changes, +21, 11q23.
‡
Because not all cases were treated, outcome measurements were not applicable.